Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Advaxis Inc.'s Stock Roared Higher in March

By George Budwell - Apr 12, 2016 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Advaxis' shares got a boost from two positive clinical updates last month.

ADXS Chart

What: Shares of the clinical-state biotech Advaxis (ADXS 9.23%) gained over 50% last month, according to data from S&P Global Market Intelligence. The main catalyst behind this monstrous surge was the news that the company's midstage study for its lead immunotherapy candidate in HPV-associated head and neck cancer, axalimogene filolisbac (AXAL), was selected as a late-breaker poster presentation at the American Association for Cancer Research (AACR) Annual Meeting scheduled to take place April 16th - 20th.

In addition, Advaxis reported encouraging results for its canine bone cancer therapy known as ADXS-HER2 that also pushed the biotech's shares higher for the month. 

So what: Advaxis' stock, along with most of its peers in the world of cancer immunotherapy, have been getting thumped since the start of 2016. The Loncar Cancer Immunotherapy ETF (CNCR 2.02%), for instance, has fallen by over 26% from its former highs last year:

CNCR Chart

The bottom line is that the market seemingly lost its appetite for risky clinical-stage biotechs at the start of the year, especially for those working on unproven therapeutic platforms like Advaxis. So, this recent uptrend in Advaxis' shares may signal the beginning of a sentiment change in the market that would obviously be bolstered by more positive clinical updates -- such as the one expected to come from Advaxis next week at the AACR meeting. 

Now what: Advaxis and its collaborators are making remarkable progress in terms of assessing the biotech's listeria-based immunotherapies across a host of indications in both humans and dogs.

Source: Advaxis

Even so, cancer immunotherapy as a whole remains a speculative bet due to its current stage of development and the fact that even big pharmas with their vast resources have recently reported disappointing clinical news for their lead immuno-oncology candidates.

That's why I think investors would be better served by using a diversified vehicle like the Loncar Cancer Immunotherapy ETF to gain exposure to this emerging field -- rather than going with a high-risk/high-reward stock like Advaxis. The Loncar Cancer Immunotherapy ETF provides investors with a compelling mix of immuno-oncology pipelines that should generate substantial returns if this field performs as expected.

Advaxis, on the other hand, is entirely dependent on its novel listeria-based platform to create value for shareholders going forward, making it a particularly high-risk stock. After all, a single negative clinical trial update, or a dreaded clinical-hold, could cause the company's shares to crumble.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Advaxis, Inc. Stock Quote
Advaxis, Inc.
ADXS
$3.55 (9.23%) $0.30
ETF Series Solutions - Loncar Cancer Immunotherapy ETF Stock Quote
ETF Series Solutions - Loncar Cancer Immunotherapy ETF
CNCR
$15.50 (2.02%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.